On August 18, 2023, Skye Bioscience, Inc. closed the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.01 USD | +10.33% |
|
+3.09% | +194.49% |
06-24 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to S&P TMI Index | CI |
06-10 | Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+194.49% | 225M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- EMBI Stock
- News Skye Bioscience, Inc.
- Skye Bioscience, Inc. announced that it has received $12 million in funding